AQST — Aquestive Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $440.73m
- $380.89m
- $50.58m
- 27
- 27
- 73
- 38
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -66.2 | -55.8 | -70.5 | -54.4 | -7.87 |
Depreciation | |||||
Non-Cash Items | 14.3 | 11.3 | 36.3 | 10.2 | 5.49 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -11.1 | -4.41 | -1.73 | 32 | -5.34 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -60.2 | -45.5 | -33 | -9.79 | -6.38 |
Capital Expenditures | -0.663 | -0.517 | -0.913 | -2.52 | -0.995 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Cash from Investing Activities | -0.663 | -0.517 | -0.913 | -2.52 | -0.995 |
Financing Cash Flow Items | -6.77 | -3.01 | -0.014 | -0.003 | 9.2 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 49.6 | 28.5 | 30.1 | 11.6 | 3.97 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -11.3 | -17.5 | -3.78 | -0.751 | -3.4 |